About Signal Pharmaceuticals
Signal Pharmaceuticals is a company based in San Diego (United States) founded in 1993 was acquired by Celgene in June 2000.. Signal Pharmaceuticals has raised $12 million across 2 funding rounds from investors including New York Life Insurance, Celgene and Robertson Stephens Partners. Signal Pharmaceuticals operates in a competitive market with competitors including eGenesis, Beam Therapeutics, Korro Bio, Scribe Therapeutics and Tessera Therapeutics, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12 M (USD)
in 2 rounds
-
Latest Funding Round
$12 M (USD), Series E
Sep 17, 1997
-
Investors
New York Life Insurance
& 5 more
-
Employee Count
Employee Count
-
Acquired by
Celgene
(Jun 30, 2000)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Signal Pharmaceuticals
Signal Pharmaceuticals has successfully raised a total of $12M across 2 strategic funding rounds. The most recent funding activity was a Series E round of $12 million completed in September 1997. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series E — $12.0M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 1997 | Amount | Series E - Signal Pharmaceuticals | Valuation |
investors |
|
| Jun, 1993 | Amount | Series D - Signal Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Signal Pharmaceuticals
Signal Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include New York Life Insurance, Celgene and Robertson Stephens Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
Global financial advisory services are provided by the firm.
|
Founded Year | Domain | Location | |
|
Mutual life insurance and asset management services are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Signal Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Signal Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Signal Pharmaceuticals Comparisons
Competitors of Signal Pharmaceuticals
Signal Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as eGenesis, Beam Therapeutics, Korro Bio, Scribe Therapeutics and Tessera Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
A CRISPR-based gene-editing platform is developed for therapeutic applications.
|
|
| domain | founded_year | HQ Location |
New genome engineering technology is provided for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Signal Pharmaceuticals
Frequently Asked Questions about Signal Pharmaceuticals
When was Signal Pharmaceuticals founded?
Signal Pharmaceuticals was founded in 1993.
Where is Signal Pharmaceuticals located?
Signal Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Signal Pharmaceuticals a funded company?
Signal Pharmaceuticals is a funded company, having raised a total of $12M across 2 funding rounds to date.
What does Signal Pharmaceuticals do?
Signal Pharmaceuticals was founded in 1993 in San Diego, United States, within the biotechnology sector. Research and development efforts are directed toward small molecule drugs that modulate disease-related genes. Advanced cellular, molecular, and genomic technologies are utilized to map gene-regulating pathways and identify proprietary targets for gene activation or deactivation. Partnerships with pharmaceutical companies are formed to advance drug discovery for disease-associated genes.
Who are the top competitors of Signal Pharmaceuticals?
Signal Pharmaceuticals's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
Who are Signal Pharmaceuticals's investors?
Signal Pharmaceuticals has 6 investors. Key investors include New York Life Insurance, Celgene, Robertson Stephens Partners, Ares Serono, and Lehman Brothers.